Table II.
Treatment recommendations
| Questions | Answers | N (%) |
|---|---|---|
| Which antihypertensive drug group do you prefer the most in your hypertensive patients? (If you prefer combined drugs, you can select more than one option.) | ACE inhibitors ARB Calcium channel blockers B-blockers Diuretics Mineralocorticoid receptor antagonists A-blockers |
75 (72.12) 50 (48.08) 68 (65.38) 18 (17.31) 38 (36.54) 5 (4.81) 3 (2.88) |
| Do you recommend electrical/medical cardioversion for rhythm control in patients with chronic atrial fibrillation? | All of them 75–99% 50–74% 25–49% < 25% None of them |
9 (8.65) 12 (11.54) 26 (25.0) 14 (13.46) 33 (31.73) 10 (9.62) |
| Which drug/method do you prefer the most for rate control in patients with chronic atrial fibrillation? | B-blockers Non-dihydropyridine calcium channel blockers Digoxin Amiodarone Sotalol Propafenone Atrioventricular node ablation/modification |
97 (93.27) 4 (3.85) 3 (2.88) 0 (0) 0 (0) 0 (0) 0 (0) |
| Do you prefer SGLT-2 inhibitors as first-line treatment in your patients with low ejection heart failure, regardless of diabetes mellitus? | Yes No Undecided No opinion |
94 (90.38) 5 (5.77) 4 (3.85) 0 (0) |
| Do you prefer SGLT-2 inhibitors to reduce heart failure-related hospitalization or CV death in patients with symptomatic HFpEF (HF with preserved EF) and/or HFmrEF (HF with mildly reduced EF)? | Yes No Undecided No opinion |
86 (82.69) 11 (10.58) 7 (6.73) 0 (0) |
| Do you prefer angiotensin receptor inhibitors (ARNI) as first-line treatment in your patients with low ejection heart failure? | Yes No Undecided No opinion |
60 (57.69) 37 (35.58) 7 (6.73) 0 (0) |
| Do you recommend medication supplements in addition to medical/interventional treatment for patients with heart failure? (You can select more than one option.) | No Vitamin Herbal products Omega 3 Probiotic |
72 (69.23) 22 (21.15) 3 (2.88) 13 (12.5) 10 (9.62) |
| Do you prefer PCSK9 inhibitors for your patients using statin + ezetimibe to reach the target LDL value? | Yes No Undecided No opinion |
23 (22.12) 59 (56.73) 18 (17.31) 4 (3.85) |
| Do you recommend aspirin for primary prophylaxis in patients with moderate to severe cardiovascular risk? | Yes No Undecided No opinion |
60 (57.69) 34 (32.69) 9 (8.65) 1 (0.96) |
| Do you routinely recommend influenza vaccination to your patients whom you follow up after acute coronary syndrome? | Never Rarely Frequently All of them No opinion |
15 (14.42) 39 (37.5) 37 (35.6) 10 (9.62) 3 (2.88) |
| Would you recommend low dose colchicine (0.5 mg 1 × 1) in ACS patients with uncontrolled or recurrent cardiovascular events under optimal medical therapy? | Never Rarely Frequently All of them No opinion |
35 (33.65) 43 (41.35) 14 (13.46) 2 (1.92) 10 (9.62) |
| Would you prefer finerenone to reduce the risk of hospitalization due to heart failure in patients with type 2 DM and chronic renal failure? | Never Rarely Frequently All of them No opinion |
47 (45.19) 26 (25.0) 6 (5.77) 0 (0) 25 (24.04) |
| Would you prefer intravenous iron carboxymaltose/iron derisomaltose treatment in patients with symptomatic HFrEF or HFmrEF with iron deficiency to reduce heart failure-related hospitalization and improve quality of life? | Never Rarely Frequently All of them No opinion |
7 (6.73) 29 (27.88) 54 (51.92) 1 (0.96) |
| Which agent do you frequently use for long-term single antiplatelet treatment in patients with acute coronary syndrome who do not need oral anticoagulants? | Acetyl salicylic acid Clopidogrel Ticagrelor Prasugrel |
69 (66.35) 33 (31.73) 2 (1.92) 0 (0) |